At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 160 enrolled
Drug / intervention
Indoximod +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study of the Combination of Indoximod and Temozolomide for Adult Patients With Temozolomide-Refractory Primary Malignant Brain Tumors
In Brief
A Phase 2 clinical trial evaluating Indoximod, Temozolomide, and 2 other interventions for Glioblastoma Multiforme and 3 related conditions. Completed, enrolled 160 participants across 17 sites.
Detailed Summary
In this study, investigators will conduct a phase I/II trial in recurrent (temozolomide resistant) glioma patients. The overall goal of this study is to provide a foundation for future studies with indoximod tested in newly diagnosed glioblastoma patients with radiation and temozolomide, or in combination with vaccine therapies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma Multiforme, Glioma, Gliosarcoma, Malignant Brain Tumor
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedFeb 2014
Enrollment StartMar 2014
Primary CompletionApr 2018
Study CompletionJun 2019
TodayJul 2026
First PostedFeb 3, 2014
Enrollment StartMar 1, 2014
Primary CompletionApr 18, 2018
Study CompletionJun 20, 2019
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 12.4 years ago
Interventions
Indoximoddrug
Temozolomidedrug
Bevacizumabdrug
Stereotactic Radiationradiation